Journal
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Volume 125, Issue -, Pages 78-86Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijbiomac.2018.12.058
Keywords
Hydroxybutyl chitosan; Bone marrow-derived mesenchymal stem cells; Keloid
Funding
- National Natural Science Foundation of China [81671828, 81801846]
- National Natural Science Foundation of China NSFC-Shandong joint fund [U1706212]
- Taishan Scholar Program, China
Ask authors/readers for more resources
Cell therapy with bone marrow-derived mesenchymal stem cells (BMSCs) is a potential method for many disease treatments, including keloid. In the present study, an Arg-Gly-Asp (RGD) modified hydroxybutyl chitosan (HBC) hydrogel (HBC-RGD) was developed to enhance the adhesion and proliferation of BMSCs within the hydrogel. The successful synthesis of HBC-RGD was confirmed by FTIR and 1H NMR. Both HBC and HBC-RGD hydrogel had desired thermosensitivity, biocompatibility and enzymatic degradability in vitro. Compared with HBC hydro gel, HBC-RGD hydrogel was more beneficial for the adhesion and proliferation of BMSCs. Furthermore, the BMSCs incorporated HBC-RGD (BMSCs/HBC-RGD) hydrogel could inhibit the proliferation of keloid fibroblasts (Kfs) and suppress the nodular collagenous fibers of keloid tissue. These results suggested that the HBC-RGD hydrogel could be applied as a potential 3D hydrogel scaffold for cell culture, and BMSCs/HBC-RGD hydrogel was potential to be applied for keloid therapy with subcutaneous in-situ injection in the future. (C) 2018 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available